Jody A. Charnow

Investigators report encouraging findings from a novel active surveillance management approach for patients with small renal masses.

New study finds comparable rates of complications and overall, cancer-specific, and metastasis-free survival rates.

Compared with TRUS biopsies, MRI fusion biopsy findings are more likely to be concordant with final prostate cancer pathology at the time of radical prostatectomy, a study found.

Investigators report finding no significant difference in biochemical recurrence-free and metastasis-free survival and freedom from treatment between men with very-low-risk and low-risk prostate cancer and those with favorable intermediate-risk disease.

Study finds that prostate cancer patients with PSA levels of 50 ng/mL or higher prior to radical prostatectomy have a 20-year cancer-specific mortality rate of 20.5%.

In a study of men who received sipuleucel-T immunotherapy for metastatic castration-resistant prostate cancer, a PSA level below 5 ng/mL at baseline was associated with significantly longer survival compared with a higher PSA level.

Patients who received intravesical docetaxel, gemcitabine, and cisplatin for BCG-refractory nonmuscle-invasive bladder cancer had initial downgrading, downstaging, or both.